Background: Vascular cognitive impairment causes significant disability in the elderly and is common following ischaemic stroke. Although the underlying mechanisms and prognostic factors remain unclear, small vessel diseases are known to contribute. Cerebral microbleeds (CMBs) are a magnetic resonance imaging (MRI) manifestation of small vessel diseases and may contribute to vascular cognitive impairment, particularly frontal-executive functions. We hypothesized that baseline CMBs would predict long-term cognitive outcome, specifically frontal-executive function. Methods: A cohort of consecutive patients found to have CMBs when first referred to a stroke clinic, together with a CMB-free control group matched for age, gender and clinicoradiological characteristics, were invited for follow-up cognitive assessment a median of 5.7 years later. MRI and detailed cognitive assessment (including current intellectual function, verbal memory, visual memory, naming skills, perceptual functions, frontal-executive functions; and speed and attention) were performed at baseline and follow-up. Patients were classified (blinded to MRI and clinical data) as impaired or unimpaired in each domain using predefined criteria. We compared the prevalence of cognitive impairments in each domain at baseline and follow-up and investigated clinical and radiological predictors [including baseline CMBs and white matter changes (WMCs)] of frontal-executive cognitive impairment. Results: Of the original cohort of 55 patients, 13 died without follow-up. Twenty-six of the surviving patients (9 with, 17 without baseline CMBs) agreed to follow-up neuropsychological assessment; 21 of these patients had a repeat MRI scan. The median number of cognitive domains impaired increased, regardless of the presence of baseline CMBs (with baseline CMBs: median 3, range 0–5 at follow-up vs. median 2, range 0–2 at baseline, p = 0.016; without CMBs: median 1.0, range 0–5 at follow-up vs. median 0, range 0–5 at baseline, p = 0.035). Frontal-executive impairment at follow-up was more prevalent in patients with baseline CMBs than in those without (78 vs. 29%, p = 0.038). The presence of baseline CMBs predicted frontal-executive impairment at follow-up (OR 8.40, 95% CI 1.27–55.39, p = 0.027). Fifty percent of patients with CMBs versus 8% of patients without baseline CMBs developed new CMBs (p = 0.047). The severity of WMCs increased; the difference was statistically significant only in patients without baseline CMBs (p = 0.027). There were no new cortical infarcts. Conclusion: In stroke clinic patients, CMBs are consistently associated with frontal-executive impairment; baseline CMBs are associated with frontal-executive impairment at follow-up after 5.7 years. The presence of CMBs has prognostic relevance for long-term cognitive outcome in stroke clinic patients, and may help to optimally target preventive strategies in individuals at highest risk of cognitive decline.

Keywords:
Cerebral microbleeds, Vascular cognitive impairment, Magnetic resonance imaging, Stroke
1.
Bowler JV: Vascular cognitive impairment. JNNP 2005;76:v35–v44.
2.
Schneider JA: Brain microbleeds and cognitive function. Stroke 2007;38:1730–1731.
3.
Purandare N: Preventing dementia: role of vascular risk factors and cerebral emboli. Br Med Bull 2009;91:49–59.
4.
Seo SW, Hwa LB, Kim EJ, et al: Clinical significance of microbleeds in subcortical vascular dementia. Stroke 2007;38:1949–1951.
5.
Werring DJ, Frazer DW, Coward LJ, et al: Cognitive dysfunction in patients with cerebral microbleeds on T2*-weighted gradient-echo MRI. Brain 2004;127:2265–2275.
6.
Liem MK, Lesnik Oberstein SA, Haan J, et al: MRI correlates of cognitive decline in CADASIL: a 7-year follow-up study. Neurology 2009;72:143–148.
7.
Qiu C, Cotch MF, Sigurdsson S, et al: Cerebral microbleeds, retinopathy and dementia: the AGES-Reykjavik study. Neurology 2010;75:2221–2228.
8.
Ballard C, Stephens S, McLaren A, Wesnes K, Kenny RA, Burton E, O’Brien J, Kalaria R: Neuropsychological deficits in older stroke patients. Ann NY Acad Sci 2002;977:179–182.
9.
Gregoire SM, Chaudhary UJ, Jäger HR, et al: The Microbleed Anatomical Rating Scale (MARS): a new reliable tool to map brain microbleeds. Neurology 2009;73:1759–1766.
10.
Wahlund L, Barkhof F, Fazekas F: A new rating scale for age-related white matter changes applicable to MRI and CT. Stroke 2001;32:1318–1322.
11.
Trennary MR, Crossen B, DeBoe J, Leber WR: Stroop Neuropsychological Screening Test (SNST). Odessa, Psychological Assessment Resources, 1989.
12.
Spreen O, Benton AL: Neurosensory Center Comprehensive Examination for Aphasia. Victoria, Neuropsychology Laboratory, University of Victoria, 1969.
13.
Army Individual Test Battery. Manual and directions for scoring. Washington, War Department, Adjunct General’s Office, 1944.
14.
Weigl E: On the psychology of so-called processes of abstraction. J Abnormal Soc Psychol 1941;36:3–33.
15.
Nelson HE: A modified card sorting test sensitive to frontal lobe defects. Cortex 1976;12:313–324.
16.
Cordonnier C, van der Flier WM, Sluimer JD, et al: Prevalence and severity of microbleeds in a memory clinic setting. Neurology 2006;66:1356–1360.
17.
Pettersen JA, Sathiyamoorthy G, Gao FQ, et al: Microbleed topography, leukoaraiosis, and cognition in probable Alzheimer disease from the Sunnybrook Dementia Study. Neurology 2008;65:790–795.
18.
Ayaz M, Boikov A, Haacke EM, et al: Imaging cerebral microbleeds using susceptibility weighted imaging: one step toward detecting vascular dementia. J Magn Res Imaging 2010;31:142–148.
© 2012 S. Karger AG, Basel
2012
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.